HROW

HarrowD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$58.00

+76.5% vs current

Most likely

Base case

Probability

Target price

$43.00

+30.9% vs current

B-

Bear case

Probability

Target price

$30.00

-8.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-05

AI commentary

Trusted-news flow in the packet is empty, social context is absent, and analyst revision coverage is unavailable, so headline buzz looks low and the memo stays in monitoring mode. Primary filings support a credible commercial-growth setup, but the deterministic prior is still neutral-to-slightly negative with low catalyst density, which argues against a stronger rating until launch execution or cleaner post-launch evidence appears.

RankAlpha Sentiment Codex - 2026-05-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventMarch 2026 incremental notes financing adds launch and BD capacity [#8-K-2026-03-27]Medium impact

Harrow completed a $50.0 million add-on 8.625% senior notes offering on March 27, 2026 and said net proceeds of about $48.7 million are intended for general corporate purposes including new product launches, product development activities, and strategic business-development opportunities. Near-term evidence will come from whether that capital translates into visible commercial or portfolio milestones rather than simply higher leverage.

2026-07-01catalystMid-2026 launch execution for BYOOVIZ and BYQLOVI [#10-K-2026-03-02]High impact

The 2025 10-K says Harrow expects to commercially launch BYOOVIZ in mid-2026 and BYQLOVI in mid-2026. For a mid-cap ophthalmology platform, launch timing, payer access, physician uptake, and early revenue contribution are the clearest forward catalysts in the current primary-source set.

2026-11-10catalystCommercial portfolio scaling must convert 2025 revenue growth into cleaner earnings support [#10-K-2026-03-02]High impact

Harrow reported 2025 net product sales of $271.9 million versus $198.6 million in 2024, while year-end cash rose to $72.9 million and management said cash should support planned 2026 operations and capital expenditures. The next leg of the story depends on whether portfolio growth and new launches offset higher operating spend and interest burden well enough to improve earnings quality.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-05 • Updated nightlySource: Internal modelMethodology